SUPPORTING INFECTIOUS DISEASE RESEARCH

## Mycobacterium tuberculosis, Strain XTB13-238

### Catalog No. NR-49373

**Product Description:** *Mycobacterium tuberculosis* (*M. tuberculosis*), strain XTB13-238 was isolated in 2011 from the sputum of a patient with tuberculosis in the Republic of Belarus. Strain XTB13-238 was deposited as resistant to amikacin, capreomycin, cycloserine, ethambutol, isoniazid, kanamycin, ofloxacin, para-aminosalicylic acid, rifampin and streptomycin.

#### Lot<sup>1</sup>: 64064237

# Manufacturing Date: 12MAY2016

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis <sup>2</sup>		
Cellular morphology	Gram-positive rods	Gram-positive rods
Colony morphology <sup>3</sup>	Report results	Irregular, slight peaked, undulate,
, , , , , , , , , , , , , , , , , , , ,		rough and cream (Figure 1)
Growth rate	≥ 7 days	21 days
Growth at 26°C	Negative	Negative
Growth at 37°C	Positive	Positive
Acid-fast stain	Positive (red colonies)	Positive (red colonies)
Pigmentation in the dark (Scotochromogen)	Negative (no pigment)	Negative (no pigment)
Photoinduction for 1 hour (Photochromogen)	Negative (no pigment)	Negative (no pigment)
Nonchromogen (no pigment)	Positive (no pigment)	Positive (no pigment)
Biochemical tests		
Niacin production <sup>4</sup>	Positive	Positive
Nitrate reduction	Positive	Positive
Pyrazinamidase	Positive	Positive
Antibiotic Susceptibility Profile		
Sensititre <sup>™</sup> System <sup>5,6</sup>		
Amikacin	Report results	> 16 µg/mL
Cycloserine	Report results	32 µg/mL
Ethambutol	Report results	8 μg/mL <sup>7</sup>
Ethionamide	Report results	> 40 µg/mL <sup>7</sup>
Isoniazid	Report results	> 4 µg/mL
Kanamycin	Report results	> 40 µg/mL
Moxifloxacin	Report results	4 μg/mL
Ofloxacin	Report results	16 μg/mL
Para-aminosalicylic acid	Report results	> 64 µg/mL <sup>7</sup>
Rifabutin	Report results	> 16 µg/mL <sup>7</sup>
Rifampin	Report results	> 16 µg/mL
Streptomycin	Report results	> 32 µg/mL <sup>7</sup>
Genotypic Analysis		
Sequencing of Heat Shock Protein 65 gene	≥ 99% sequence identity to	100% sequence identity to
(~ 430 base pairs)	M. tuberculosis, strain XTB13-238	M. tuberculosis, strain XTB13-238
	(GenBank: JLHQ01000001.1)	(GenBank: JLHQ01000001.1) <sup>8</sup>
Purity (post-freeze)		
Middlebrook 7H10 agar with OADC enrichment <sup>9</sup>	Growth consistent with expected	Growth consistent with expected
	colony morphology	colony morphology
Tryptic Soy agar <sup>10</sup>	Report results	No growth
Viability (post-freeze) <sup>3</sup>	Growth	Growth

<sup>1</sup>NR-49373 was produced by inoculation of the deposited material into Middlebrook 7H9 broth with ADC enrichment. Broth inoculum was added to Middlebrook 7H10 agar with OADC enrichment kolles, which were grown for 63 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> to produce this lot.

<sup>2</sup>Information on Mycobacterium testing is available from Ribón, W. "Biochemical Isolation and Identification of Mycobacteria." <u>Biochemical Testing</u>. (2012) Jose C. Jimenez-Lopez (Ed.), InTech, <u>http://www.intechopen.com/books/biochemical-testing/biochemical-isolation-and-identification-of-</u>

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 DICII RESOURCES

# **Certificate of Analysis for NR-49373**

SUPPORTING INFECTIOUS DISEASE RESEARCH

mycobacteria and Lévy-Frébault, V. V. and F. Portaels. "Proposed Minimal Standards for the Genus *Mycobacterium* and for Description of New Slowly Growing *Mycobacterium* Species." Int. J. Syst. Bacteriol. 42 (1992): 315-323. PubMed: 1581193.

<sup>3</sup>21 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Middlebrook 7H10 agar with OADC enrichment

<sup>4</sup>All mycobacteria produce niacin but only *M. tuberculosis* accumulates it, resulting in a positive test for *M. tuberculosis*.

<sup>5</sup>Sensititre<sup>™</sup> System *Mycobacterium tuberculosis* MIC Plate, Thermo Scientific<sup>™</sup>, catalog number MYCOTB

<sup>6</sup>Minimum Inhibitory Concentration (MIC); No Clinical & Laboratory Standards Institute (CLSI) interpretations of the Sensititre<sup>™</sup> System data for *M. tuberculosis* are currently available.

<sup>7</sup>For streptomycin, ethionamide, para-aminosalicylic acid, rifabutin and ethambutol, the endpoint for these drugs is determined by the well with approximately 80% inhibition of growth compared to the positive control well with no drug.

<sup>8</sup>Also consistent with *M. africanum*, *M. bovis*, *M. canettii* and *M. microti* 

<sup>9</sup>Purity of this lot was assessed for 50 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.

<sup>10</sup>Purity of this lot was assessed for 21 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>.

#### Figure 1: Colony Morphology



Date: 10 NOV 2017

Signature:

**BEI Resources Authentication** 

ATCC<sup>®</sup>, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC<sup>®</sup>'s knowledge.

Support Provided by NIAID

ATCC<sup>®</sup> is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.